Compare Stocks: IMCR, CGON, MIRM, and XENE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$75.10 +0.3%	$67.12	$23.65 ▼ $77.00	$6.60B	0.23	925,978 shs	610,786 shs
IMCR Immunocore	$34.00 -1.4%	$31.64	$27.56 ▼ $40.71	$1.75B	0.74	545,841 shs	492,085 shs
MIRM Mirum Pharmaceuticals	$100.65 +6.9%	$110.33	$57.79 ▼ $130.00	$5.74B	0.52	701,506 shs	850,711 shs
XENE Xenon Pharmaceuticals	$63.36 -1.8%	$60.24	$32.78 ▼ $72.66	$6.24B	0.62	804,601 shs	720,234 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+0.33%	+5.49%	+7.59%	+7.87%	+196.96%
IMCR Immunocore	-1.45%	+0.56%	+0.65%	+14.94%	+5.92%
MIRM Mirum Pharmaceuticals	+6.95%	-5.00%	-21.72%	-6.08%	+88.52%
XENE Xenon Pharmaceuticals	-1.84%	+1.10%	-9.42%	+12.26%	+84.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$75.10 +0.3%	$67.12	$23.65 ▼ $77.00	$6.60B	0.23	925,978 shs	610,786 shs
IMCR Immunocore	$34.00 -1.4%	$31.64	$27.56 ▼ $40.71	$1.75B	0.74	545,841 shs	492,085 shs
MIRM Mirum Pharmaceuticals	$100.65 +6.9%	$110.33	$57.79 ▼ $130.00	$5.74B	0.52	701,506 shs	850,711 shs
XENE Xenon Pharmaceuticals	$63.36 -1.8%	$60.24	$32.78 ▼ $72.66	$6.24B	0.62	804,601 shs	720,234 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+0.33%	+5.49%	+7.59%	+7.87%	+196.96%
IMCR Immunocore	-1.45%	+0.56%	+0.65%	+14.94%	+5.92%
MIRM Mirum Pharmaceuticals	+6.95%	-5.00%	-21.72%	-6.08%	+88.52%
XENE Xenon Pharmaceuticals	-1.84%	+1.10%	-9.42%	+12.26%	+84.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.71	Moderate Buy	$83.18	10.76% Upside
IMCR Immunocore	2.55	Moderate Buy	$57.29	68.49% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$137.33	36.45% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$77.13	21.74% Upside

Current Analyst Ratings Breakdown

Latest IMCR, CGON, MIRM, and XENE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	IMCR Immunocore	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$43.00
8/7/2026	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$82.00 ➝ $81.00
8/7/2026	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$81.00 ➝ $79.00
8/7/2026	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $85.00
8/7/2026	CGON CG Oncology	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$82.00 ➝ $85.00
8/6/2026	MIRM Mirum Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
8/6/2026	MIRM Mirum Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$123.00
8/6/2026	MIRM Mirum Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$137.00
8/6/2026	MIRM Mirum Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$148.00 ➝ $135.00
8/6/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	MIRM Mirum Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$145.00 ➝ $140.00

(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,639.56	N/A	N/A	$9.33 per share	8.05
IMCR Immunocore	$400.02M	4.32	N/A	N/A	$7.52 per share	4.52
MIRM Mirum Pharmaceuticals	$521.31M	11.77	$0.05 per share	1,846.15	($0.17) per share	-592.06
XENE Xenon Pharmaceuticals	$7.50M	816.67	N/A	N/A	$7.53 per share	8.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.33	N/A	N/A	N/A	-3,602.68%	-26.58%	-25.34%	N/A
IMCR Immunocore	-$35.51M	-$0.55	N/A	52.31	N/A	-4.20%	-4.63%	-1.67%	N/A
MIRM Mirum Pharmaceuticals	-$23.36M	-$13.61	N/A	774.23	N/A	-139.18%	-36.28%	-8.54%	N/A
XENE Xenon Pharmaceuticals	-$345.91M	-$4.70	N/A	N/A	N/A	N/A	-49.52%	-46.72%	N/A

Latest IMCR, CGON, MIRM, and XENE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/6/2026	Q2 2026	IMCR Immunocore	-$0.01	-$0.02	-$0.01	-$0.02	$148.52 million	$115.93 million
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million
5/8/2026	Q1 2026	CGON CG Oncology	-$0.58	-$0.71	-$0.13	-$0.71	$0.45 million	$1.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	31.30	31.25
IMCR Immunocore	1.00	4.18	4.15
MIRM Mirum Pharmaceuticals	1.28	2.86	1.99
XENE Xenon Pharmaceuticals	N/A	27.79	27.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
IMCR Immunocore	84.50%
MIRM Mirum Pharmaceuticals	N/A
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
IMCR Immunocore	10.10%
MIRM Mirum Pharmaceuticals	8.32%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	61	88.20 million	83.97 million	Optionable
IMCR Immunocore	320	50.87 million	45.73 million	Optionable
MIRM Mirum Pharmaceuticals	140	60.98 million	55.91 million	Optionable
XENE Xenon Pharmaceuticals	210	96.67 million	93.85 million	Optionable

IMCR, CGON, MIRM, and XENE Headlines

Recent News About These Companies

Xenon anticipates AZK NDA submission later this quarter, while funding operations into 2029

August 7 at 10:06 PM | seekingalpha.com

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

August 7 at 10:06 PM | finance.yahoo.com

Xenon Pharmaceuticals Q2 Earnings Call Highlights

August 7 at 4:03 PM | marketbeat.com

XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus

August 7 at 11:16 AM | zacks.com

California State Teachers Retirement System Buys 36,183 Shares of Xenon Pharmaceuticals Inc. $XENE

August 7 at 3:04 AM | marketbeat.com

Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript

August 7 at 2:00 AM | seekingalpha.com

Xenon Pharmaceuticals Q2 Loss Widens

August 7 at 1:48 AM | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results

August 6 at 12:25 AM | marketbeat.com

Xenon Reports Q2 2026 Financial Results and Provides Business Update

August 6 at 8:47 PM | markets.businessinsider.com

Xenon Pharma Q2 2026 earnings preview

August 6 at 5:46 AM | msn.com

Xenon Pharmaceuticals Inc. $XENE Shares Bought by Sei Investments Co.

August 4, 2026 | marketbeat.com

Xenon Pharmaceuticals (XENE) to Release Earnings on Thursday

August 2, 2026 | marketbeat.com

Lazard Asset Management LLC Sells 27,908 Shares of Xenon Pharmaceuticals Inc. $XENE

August 2, 2026 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Rating Increased to Sell at Wall Street Zen

August 1, 2026 | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Raised to Sell at Wall Street Zen

August 1, 2026 | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2026 | financialpost.comF

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2026 | globenewswire.com

Janus Henderson Group PLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE

July 31, 2026 | marketbeat.com

Renaissance Technologies LLC Takes $17.47 Million Position in Xenon Pharmaceuticals Inc. $XENE

July 31, 2026 | marketbeat.com

Xenon to Report Q2 2026 Financial Results on August 6, 2026

July 30, 2026 | financialpost.comF

Xenon to Report Q2 2026 Financial Results on August 6, 2026

July 30, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR, CGON, MIRM, and XENE Company Descriptions

CG Oncology NASDAQ:CGON

$75.10 +0.25 (+0.33%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$72.20 -2.90 (-3.86%)

As of 08/7/2026 07:34 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Immunocore NASDAQ:IMCR

$34.00 -0.50 (-1.45%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$33.75 -0.25 (-0.74%)

As of 08/7/2026 07:34 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Mirum Pharmaceuticals NASDAQ:MIRM

$100.65 +6.54 (+6.95%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$100.74 +0.09 (+0.09%)

As of 08/7/2026 07:34 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Xenon Pharmaceuticals NASDAQ:XENE

$63.36 -1.19 (-1.84%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$63.42 +0.06 (+0.10%)

As of 08/7/2026 07:34 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMCR, CGON, MIRM, and XENE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMCR, CGON, MIRM, and XENE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMCR, CGON, MIRM, and XENE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR, CGON, MIRM, and XENE Company Descriptions

CG Oncology NASDAQ:CGON

Immunocore NASDAQ:IMCR

Mirum Pharmaceuticals NASDAQ:MIRM

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMCR, CGON, MIRM, and XENE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMCR, CGON, MIRM, and XENE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMCR, CGON, MIRM, and XENE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMCR, CGON, MIRM, and XENE Company Descriptions

CG Oncology NASDAQ:CGON

Immunocore NASDAQ:IMCR

Mirum Pharmaceuticals NASDAQ:MIRM

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools